Developer docs
API playgroundTry for free, no card

Search company profiles

Edenbridge Pharmaceuticals

Full company profile

uuid000ho8h

Namestring
Edenbridge Pharmaceuticals
Legal namestring
Edenbridge Pharmaceuticals, LLC
Company typeenum
Private
Founded yearint
2008
Descriptiontext

Edenbridge Pharmaceuticals, LLC is a privately held specialty pharmaceutical company founded in 2008 and headquartered in Parsippany, New Jersey. The company focuses on identifying, developing, and marketing FDA-approved generic prescription pharmaceutical products in the United States. Its portfolio is narrowly concentrated on two generic formulations: Bumetanide Tablets USP (an authorized generic of Validus Pharmaceuticals' Bumex®, available in 0.5mg, 1mg, and 2mg strengths for the treatment of edema associated with congestive heart failure, hepatic, and renal diseases) and Ivermectin Tablets USP (a generic version of Merck's Stromectol®, 3mg strength, used to treat parasitic infections including strongyloidiasis, onchocerciasis, scabies, and head lice). Both products are manufactured to USP standards with specific tablet characteristics (color, shape, engraving codes) consistent with bioequivalence requirements.

The company's go-to-market relies on an enterprise field sales motion backed by dedicated customer service teams accessible by phone, email, and fax, with revenue generated through one-time product sales to healthcare providers, pharmacies, and pharmaceutical distributors. Distribution is intermediated through the three largest U.S. pharmaceutical wholesalers — McKesson, Cardinal Health, and HD Smith — providing national channel reach. Pricing is not publicly disclosed and is negotiated directly with customers via the customer service team. The company holds licensing/authorization relationships with Validus Pharmaceuticals (for Bumex authorized generic) and Merck & Co. (for Stromectol generic).

As of October 1, 2024, Edenbridge Pharmaceuticals, LLC began doing business as Dexcel Pharma USA, signaling a corporate identity rebrand and likely integration with a broader specialty pharmaceutical portfolio under the Dexcel brand. The company operates with 11–50 employees and is privately held with no publicly disclosed revenue or detailed ownership structure. Funding history includes a 2018 capital infusion from Tailwind Capital. Leadership comprises CEO Douglas S. Boothe and founder Patrick Chu (President & Co-Founder).

Short descriptiontext

Edenbridge Pharmaceuticals is a privately held U.S. specialty pharmaceutical company that markets two FDA-approved generic prescription products — Bumetanide and Ivermectin tablets — distributed through McKesson, Cardinal Health, and HD Smith to U.S. healthcare providers and pharmacies, and now operating as Dexcel Pharma USA.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersParsippany, United States
HQ citystring
Parsippany
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
generic pharmaceuticals, prescription medications, authorized generics, loop diuretics, antiparasitic drugs
Industry1 code
PRIMARYHLAIABAD
Oral Solid Dose (OSD) Generics
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Generic Pharmaceuticals
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

Revenue generated through sale of generic pharmaceutical products (Bumetanide and Ivermectin tablets) to healthcare providers, pharmacies, and distributors. Products sold as prescription pharmaceuticals with distribution through wholesale pharmaceutical channels.

edenbridgepharma.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Personnel, Operations, Marketing or Sales, Technology or R&D, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Edenbridge Pharmaceuticals is a specialty pharmaceutical company that identifies, develops, and markets FDA-approved generic prescription pharmaceutical products. Its focused product portfolio consists of two core therapeutics: Bumetanide Tablets USP (an authorized generic of Bumex®) for the treatment of edema associated with congestive heart failure, hepatic, and renal diseases, and Ivermectin Tablets USP (a generic of Stromectol®) for parasitic infections. Products are distributed through major U.S. pharmaceutical wholesale distributors and direct customer service channels.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • FDA-approved generic alternatives provide bioequivalent therapeutic effects at potentially lower costs
Product overview1 text field

Edenbridge Pharmaceuticals is a generic pharmaceutical company offering a focused portfolio of FDA-approved generic medications. The product portfolio centers on two core therapeutics: Bumetanide Tablets, USP (an authorized generic of Bumex®) available in 0.5mg, 1mg, and 2mg strengths for edema treatment, and Ivermectin Tablets, USP (a generic of Stromectol®) in 3mg strength for parasitic infections. Products are distributed through major pharmaceutical wholesalers including McKesson, Cardinal, and HD Smith. As of October 2024, the company rebranded to Dexcel Pharma USA.

Product and service1 record
1Bumetanide Tablets, USP
Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierMinorTypeOthers
Description

Edenbridge Pharmaceuticals produces an authorized generic version of Validus Pharmaceuticals' Bumex® (Bumetanide) product. This relationship allows Edenbridge to manufacture and distribute the authorized generic version.

Strategic tierMinorTypeOthers
Description

Edenbridge Pharmaceuticals produces a generic version of Merck's Stromectol® (Ivermectin) product. This is a standard generic pharmaceutical licensing arrangement.

3McKesson
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

McKesson distributes Edenbridge's Ivermectin 3mg tablets (NDC 42799-806-01) as part of its pharmaceutical wholesale operations. Item #3404654ABC.

edenbridgepharma.com
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Cardinal Health distributes Edenbridge's Ivermectin 3mg tablets (NDC 42799-806-01) as part of its pharmaceutical wholesale network.

5HD Smith
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

HD Smith distributes Edenbridge's Ivermectin 3mg tablets (NDC 42799-806-01) as part of its pharmaceutical wholesale operations.

edenbridgepharma.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Brand owner of Bumex® and Edenbridge's direct licensing partner for the authorized generic Bumetanide business. Comparable as a small specialty pharmaceutical company marketing prescription products through US distribution channels.

TypeDirect peer
Description

Privately held US specialty/generic pharmaceutical company with a comparable small-headcount operating model focused on niche generic and specialty prescription products distributed through the Big-3 wholesalers.

TypeDirect peer
Description

Specialty generic pharmaceutical company that develops, manufactures, and markets niche prescription generics. Closely comparable in business model, distribution channels, and focus on limited-competition generic opportunities.

TypeDirect peer
Description

Smaller specialty generic pharmaceutical company marketing niche prescription products through US wholesale distribution. Comparable in scale and product-portfolio concentration.

5Padagis
TypeDirect peer
Description

Specialty generic pharmaceutical company (formerly Perrigo's generics prescription business) focused on niche generic prescription products including topical and difficult-to-formulate generics. Similar target customer base and distribution model.

TypeBroad incumbent
Description

Large US-based generic and specialty pharmaceutical manufacturer. A broader incumbent offering extensive generic injectable, oral solid dose, and specialty products across most therapeutic categories.

TypeBroad incumbent
Description

Major global generic pharmaceutical manufacturer with substantial US commercial presence. Competes indirectly in the same generic therapeutic categories through broader portfolio scale.

TypeBroad incumbent
Description

Specialty and generics pharmaceutical company with a portfolio that overlaps Edenbridge's therapeutic focus areas (e.g., cardiovascular and specialty prescription products). Larger incumbent with broader commercial reach.

9Heritage Pharmaceuticals (Aceto-owned)
TypeEmerging player
Description

Generic pharmaceutical company marketing prescription generic products in similar therapeutic categories. Comparable scale and go-to-market approach through Big-3 wholesalers.

TypeEmerging player
Description

India-headquartered global generic pharmaceutical company with growing US generic business. Emerging competitive presence in oral solid dose generics distributed through US wholesalers.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Edenbridge Pharmaceuticals

Generic Pharmaceuticalsedenbridgepharma.com

Edenbridge Pharmaceuticals is a privately held U.S. specialty pharmaceutical company that markets two FDA-approved generic prescription products — Bumetanide and Ivermectin tablets — distributed through McKesson, Cardinal Health, and HD Smith to U.S. healthcare providers and pharmacies, and now operating as Dexcel Pharma USA.

What Edenbridge Pharmaceuticals does

Edenbridge Pharmaceuticals, LLC is a privately held specialty pharmaceutical company founded in 2008 and headquartered in Parsippany, New Jersey. The company focuses on identifying, developing, and marketing FDA-approved generic prescription pharmaceutical products in the United States. Its portfolio is narrowly concentrated on two generic formulations: Bumetanide Tablets USP (an authorized generic of Validus Pharmaceuticals' Bumex®, available in 0.5mg, 1mg, and 2mg strengths for the treatment of edema associated with congestive heart failure, hepatic, and renal diseases) and Ivermectin Tablets USP (a generic version of Merck's Stromectol®, 3mg strength, used to treat parasitic infections including strongyloidiasis, onchocerciasis, scabies, and head lice). Both products are manufactured to USP standards with specific tablet characteristics (color, shape, engraving codes) consistent with bioequivalence requirements.

The company's go-to-market relies on an enterprise field sales motion backed by dedicated customer service teams accessible by phone, email, and fax, with revenue generated through one-time product sales to healthcare providers, pharmacies, and pharmaceutical distributors. Distribution is intermediated through the three largest U.S. pharmaceutical wholesalers — McKesson, Cardinal Health, and HD Smith — providing national channel reach. Pricing is not publicly disclosed and is negotiated directly with customers via the customer service team. The company holds licensing/authorization relationships with Validus Pharmaceuticals (for Bumex authorized generic) and Merck & Co. (for Stromectol generic).

As of October 1, 2024, Edenbridge Pharmaceuticals, LLC began doing business as Dexcel Pharma USA, signaling a corporate identity rebrand and likely integration with a broader specialty pharmaceutical portfolio under the Dexcel brand. The company operates with 11–50 employees and is privately held with no publicly disclosed revenue or detailed ownership structure. Funding history includes a 2018 capital infusion from Tailwind Capital. Leadership comprises CEO Douglas S. Boothe and founder Patrick Chu (President & Co-Founder).

Edenbridge Pharmaceuticals firmographics

Firmographics
Name
Edenbridge Pharmaceuticals
Legal name
Edenbridge Pharmaceuticals, LLC
Website
https://edenbridgepharma.com
Company type
Private
Founded year
2008
Operating status
Operating
Headcount range
51–100 employees
Short description
Edenbridge Pharmaceuticals is a privately held U.S. specialty pharmaceutical company that markets two FDA-approved generic prescription products — Bumetanide and Ivermectin tablets — distributed through McKesson, Cardinal Health, and HD Smith to U.S. healthcare providers and pharmacies, and now operating as Dexcel Pharma USA.
Ownership category
akta.pro rank

Edenbridge Pharmaceuticals industry classification

Industry
Product category
Generic Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIABAD
Oral Solid Dose (OSD) Generics

Keywords

  • Generic pharmaceuticals
  • Prescription medications
  • Authorized generics
  • Loop diuretics
  • Antiparasitic drugs

Where Edenbridge Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Parsippany
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Edenbridge Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

  1. Pharmaceutical Product Sales: Revenue generated through sale of generic pharmaceutical products (Bumetanide and Ivermectin tablets) to healthcare providers, pharmacies, and distributors. Products sold as prescription pharmaceuticals with distribution through wholesale pharmaceutical channels.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels3 records

Edenbridge Pharmaceuticals product offering

Product offering

Core offering

Edenbridge Pharmaceuticals is a specialty pharmaceutical company that identifies, develops, and markets FDA-approved generic prescription pharmaceutical products. Its focused product portfolio consists of two core therapeutics: Bumetanide Tablets USP (an authorized generic of Bumex®) for the treatment of edema associated with congestive heart failure, hepatic, and renal diseases, and Ivermectin Tablets USP (a generic of Stromectol®) for parasitic infections. Products are distributed through major U.S. pharmaceutical wholesale distributors and direct customer service channels.

Product overview

Edenbridge Pharmaceuticals is a generic pharmaceutical company offering a focused portfolio of FDA-approved generic medications. The product portfolio centers on two core therapeutics: Bumetanide Tablets, USP (an authorized generic of Bumex®) available in 0.5mg, 1mg, and 2mg strengths for edema treatment, and Ivermectin Tablets, USP (a generic of Stromectol®) in 3mg strength for parasitic infections. Products are distributed through major pharmaceutical wholesalers including McKesson, Cardinal, and HD Smith. As of October 2024, the company rebranded to Dexcel Pharma USA.

Differentiator

Problem solved

Functional benefit

Products and services

  • Bumetanide Tablets, USP

Quantifiable outcome

  • FDA-approved generic alternatives provide bioequivalent therapeutic effects at potentially lower costs

Companies that use Edenbridge Pharmaceuticals

Customer profile

Segments3 records

Ideal customer profiles2 records

Edenbridge Pharmaceuticals technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Edenbridge Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered minor and core.

  • Validus Pharmaceuticals LLCminorOthersEdenbridge Pharmaceuticals produces an authorized generic version of Validus Pharmaceuticals' Bumex® (Bumetanide) product. This relationship allows Edenbridge to manufacture and distribute the authorized generic version.
  • Merck & Co., Inc.minorOthersEdenbridge Pharmaceuticals produces a generic version of Merck's Stromectol® (Ivermectin) product. This is a standard generic pharmaceutical licensing arrangement.
  • McKessoncoreChannel Partner/ Reseller/ DistributorMcKesson distributes Edenbridge's Ivermectin 3mg tablets (NDC 42799-806-01) as part of its pharmaceutical wholesale operations. Item #3404654ABC.
  • Cardinal HealthcoreChannel Partner/ Reseller/ DistributorCardinal Health distributes Edenbridge's Ivermectin 3mg tablets (NDC 42799-806-01) as part of its pharmaceutical wholesale network.
  • HD SmithcoreChannel Partner/ Reseller/ DistributorHD Smith distributes Edenbridge's Ivermectin 3mg tablets (NDC 42799-806-01) as part of its pharmaceutical wholesale operations.

Scale indicators2 records

Recent moves6 records

Expansion highlights3 records

Edenbridge Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • Validus Pharmaceuticals: Brand owner of Bumex® and Edenbridge's direct licensing partner for the authorized generic Bumetanide business. Comparable as a small specialty pharmaceutical company marketing prescription products through US distribution channels.
  • Upsher-Smith Laboratories: Privately held US specialty/generic pharmaceutical company with a comparable small-headcount operating model focused on niche generic and specialty prescription products distributed through the Big-3 wholesalers.
  • ANI Pharmaceuticals: Specialty generic pharmaceutical company that develops, manufactures, and markets niche prescription generics. Closely comparable in business model, distribution channels, and focus on limited-competition generic opportunities.
  • Westminster Pharmaceuticals: Smaller specialty generic pharmaceutical company marketing niche prescription products through US wholesale distribution. Comparable in scale and product-portfolio concentration.
  • Padagis: Specialty generic pharmaceutical company (formerly Perrigo's generics prescription business) focused on niche generic prescription products including topical and difficult-to-formulate generics. Similar target customer base and distribution model.

Broad incumbents

  • Amneal Pharmaceuticals: Large US-based generic and specialty pharmaceutical manufacturer. A broader incumbent offering extensive generic injectable, oral solid dose, and specialty products across most therapeutic categories.
  • Lupin Pharmaceuticals: Major global generic pharmaceutical manufacturer with substantial US commercial presence. Competes indirectly in the same generic therapeutic categories through broader portfolio scale.
  • Endo Pharmaceuticals: Specialty and generics pharmaceutical company with a portfolio that overlaps Edenbridge's therapeutic focus areas (e.g., cardiovascular and specialty prescription products). Larger incumbent with broader commercial reach.

Emerging players

  • Heritage Pharmaceuticals (Aceto-owned): Generic pharmaceutical company marketing prescription generic products in similar therapeutic categories. Comparable scale and go-to-market approach through Big-3 wholesalers.
  • Glenmark Pharmaceuticals: India-headquartered global generic pharmaceutical company with growing US generic business. Emerging competitive presence in oral solid dose generics distributed through US wholesalers.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

Edenbridge Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Edenbridge Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles2 records

Edenbridge Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Edenbridge Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Edenbridge Pharmaceuticals

What does Edenbridge Pharmaceuticals do?

Edenbridge Pharmaceuticals is a specialty pharmaceutical company that identifies, develops, and markets FDA-approved generic prescription pharmaceutical products. Its focused product portfolio consists of two core therapeutics: Bumetanide Tablets USP (an authorized generic of Bumex®) for the treatment of edema associated with congestive heart failure, hepatic, and renal diseases, and Ivermectin Tablets USP (a generic of Stromectol®) for parasitic infections. Products are distributed through major U.S. pharmaceutical wholesale distributors and direct customer service channels.

Is Edenbridge Pharmaceuticals a public or private company?

Edenbridge Pharmaceuticals is a private company. It is classified as venture growth investor backed and is currently operating.

When was Edenbridge Pharmaceuticals founded?

Edenbridge Pharmaceuticals was founded in 2008. It employs 51 to 100 people.

Where is Edenbridge Pharmaceuticals based?

Edenbridge Pharmaceuticals is headquartered in Parsippany, United States, in the North America region.

How does Edenbridge Pharmaceuticals make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are Edenbridge Pharmaceuticals's main competitors?

Direct peers on record are Validus Pharmaceuticals, Upsher-Smith Laboratories, ANI Pharmaceuticals, Westminster Pharmaceuticals and Padagis. Broad incumbents are Amneal Pharmaceuticals, Lupin Pharmaceuticals and Endo Pharmaceuticals. Emerging players are Heritage Pharmaceuticals (Aceto-owned) and Glenmark Pharmaceuticals.

Does Edenbridge Pharmaceuticals have an API?

No public API is recorded for Edenbridge Pharmaceuticals.

What industry is Edenbridge Pharmaceuticals in?

Edenbridge Pharmaceuticals's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIABAD, Oral Solid Dose (OSD) Generics. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceEdenbridge Pharmaceuticals Announces the Launch of DARTISLA ODTEdenbridge Pharmaceuticals announced the U.S. launch of DARTISLA ODT, an orally disintegrating glycopyrrolate tablet, through Phil and retail pharmacies. The company sponsors a copay program offering $0 at Phil or $20 at other pharmacies. The FDA approved the product in December 2021.Business Wire BlogEdenbridge Pharmaceuticals Announces the Launch of DARTISLA ODTEdenbridge Pharmaceuticals announced the U.S. launch of DARTISLA ODT, an orally disintegrating tablet of glycopyrrolate, for reducing peptic ulcer symptoms. The company sponsors a copay program offering $0 at Phil or $20 at other pharmacies. The FDA approved the product on December 16, 2021.PR NewswireEdenbridge Pharmaceuticals kondigt aan dat Yargesa (miglustat-capsules 100mg) een positieve beoordeling van de CHMP ontvangtEdenbridge Pharmaceuticals announced that its generic drug Yargesa (miglustat capsules 100mg) received a positive opinion from the CHMP, the European Medicines Agency's scientific committee. If approved by the European Commission in the coming months, Yargesa would become the first generic version of Actelion's Zavesca® approved through the centralized procedure for sale across all EU member states. The total EU market for miglustat capsules is estimated at €50 million, and Edenbridge is exploring partnership, licensing, and divestiture opportunities.PR NewswireEdenbridge Pharmaceuticals ha annunciato che Yargesa (capsule di miglustat da 100mg) ha ricevuto parere favorevole dal CHMPEdenbridge Pharmaceuticals announced that its generic drug Yargesa (miglustat 100mg capsules) received a positive opinion from the CHMP, potentially becoming the first generic version of Actelion's Zavesca® approved in the European Union through the centralized procedure. The EU market for miglustat capsules is estimated at 50 million euros, with a final decision from the European Commission expected within a few months. Edenbridge stated it is exploring partnership, licensing, and divestment opportunities for the product.PR NewswireEdenbridge Pharmaceuticals anuncia que Yargesa (100mg miglustat cápsulas) recibe una opinión positiva del CHMPEdenbridge Pharmaceuticals announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Yargesa (100mg miglustat capsules), a generic version of Actelion's Zavesca. If approved by the European Commission, Yargesa would become the first generic version of Zavesca approved through the centralized procedure for sale across all EMA member states. The EU market for miglustat capsules is estimated at approximately 50 million euros, and Edenbridge is exploring partnership, licensing, and divestiture opportunities.PR NewswireEdenbridge Pharmaceuticals gibt bekannt, dass Yargesa (Kapseln mit 100 mg Miglustat) eine positive Stellungnahme der CHMP erhältEdenbridge Pharmaceuticals announced that the Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for Yargesa (100mg Miglustat capsules), a generic version of Actelion's Zavesca® for treating mild to moderate Gaucher disease Type 1. The EU market for Miglustat capsules is estimated at €50 million, and the European Commission is expected to make a final approval decision in the coming months. If approved, Yargesa would become the first generic version of Zavesca® to receive centralized marketing authorization across all EMA member states.